NO991483L - Insulin C-peptider - Google Patents
Insulin C-peptiderInfo
- Publication number
- NO991483L NO991483L NO991483A NO991483A NO991483L NO 991483 L NO991483 L NO 991483L NO 991483 A NO991483 A NO 991483A NO 991483 A NO991483 A NO 991483A NO 991483 L NO991483 L NO 991483L
- Authority
- NO
- Norway
- Prior art keywords
- peptide
- fragment
- peptides
- atpase activity
- stimulate
- Prior art date
Links
- 108010075254 C-Peptide Proteins 0.000 title abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
- 102000004877 Insulin Human genes 0.000 title 1
- 108090001061 Insulin Proteins 0.000 title 1
- 229940125396 insulin Drugs 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 108091006112 ATPases Proteins 0.000 abstract 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 208000002249 Diabetes Complications Diseases 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 230000003592 biomimetic effect Effects 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 108010038088 glutamyl-glycyl-seryl-leucyl-glutamine Proteins 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- 210000005233 tubule cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9603533A SE520392C2 (sv) | 1996-09-27 | 1996-09-27 | Specifika peptider för behandling av diabetes mellitus |
| PCT/GB1997/002627 WO1998013384A1 (en) | 1996-09-27 | 1997-09-26 | Insulin c-peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991483D0 NO991483D0 (no) | 1999-03-26 |
| NO991483L true NO991483L (no) | 1999-05-18 |
Family
ID=20404052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991483A NO991483L (no) | 1996-09-27 | 1999-03-26 | Insulin C-peptider |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6610649B2 (xx) |
| EP (1) | EP0938503B1 (xx) |
| JP (1) | JP2001500893A (xx) |
| KR (1) | KR20000048643A (xx) |
| AT (1) | ATE347562T1 (xx) |
| AU (1) | AU741901B2 (xx) |
| BG (1) | BG103362A (xx) |
| BR (1) | BR9711573A (xx) |
| CA (1) | CA2266416C (xx) |
| CZ (1) | CZ108599A3 (xx) |
| DE (1) | DE69737065T2 (xx) |
| DK (1) | DK0938503T3 (xx) |
| ES (1) | ES2278394T3 (xx) |
| HU (1) | HUP0000432A3 (xx) |
| IL (1) | IL129143A0 (xx) |
| IS (1) | IS5008A (xx) |
| NO (1) | NO991483L (xx) |
| NZ (1) | NZ335231A (xx) |
| PL (1) | PL332494A1 (xx) |
| RU (1) | RU2206336C2 (xx) |
| SE (1) | SE520392C2 (xx) |
| SK (1) | SK39499A3 (xx) |
| TR (1) | TR199900694T2 (xx) |
| WO (1) | WO1998013384A1 (xx) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0022342D0 (en) * | 2000-09-12 | 2000-10-25 | Creative Peptides Sweden Ab | Reduction of the electrocardiographic QT interval |
| DE10055857A1 (de) * | 2000-11-10 | 2002-08-22 | Creative Peptides Sweden Ab Dj | Neue pharmazeutische Depotformulierung |
| US20030198666A1 (en) * | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| EP1592438B1 (en) * | 2003-01-06 | 2014-02-26 | Emisphere Technologies, Inc. | Night-time oral insulin therapy |
| US20050026826A1 (en) * | 2003-01-17 | 2005-02-03 | Margarethe Hoenig | Feline proinsulin, insulin and constituent peptides |
| US20050203001A1 (en) * | 2004-03-05 | 2005-09-15 | Emisphere Technologies, Inc. | Oral insulin therapies and protocol |
| GB0323979D0 (en) | 2003-10-13 | 2003-11-19 | Creative Peptides Sweden Ab | Therapeutic applications for c-peptide |
| WO2005117937A2 (en) * | 2004-05-27 | 2005-12-15 | Essential Skincare Llc | Alpha-1- acid glycoprotein for the treatment of diabetes |
| US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
| GB0601950D0 (en) * | 2006-01-31 | 2006-03-15 | Creative Peptides Sweden Ab | Compositions and methods of treating diabetes |
| JP5256199B2 (ja) * | 2006-08-07 | 2013-08-07 | テヴァ バイオファーマシューティカルズ ユーエスエー，インコーポレーティッド | アルブミン−インスリン融合タンパク質 |
| RU2010113980A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение с-пептида инсулина отдельно или в сочетании с glp-1 в качестве терапевтического средства |
| GB0723250D0 (en) * | 2007-11-28 | 2008-01-09 | Univ Leeds | Compositions and methods for reducing macrovascular complications in diabetic patients |
| EP2334338A2 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of c-peptides |
| EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
| US8410049B2 (en) * | 2009-10-28 | 2013-04-02 | Cebix | Methods and kits for preventing hypoglycemia |
| WO2011146518A2 (en) | 2010-05-17 | 2011-11-24 | Cebix Inc. | Pegylated c-peptide |
| CN103458911B (zh) | 2011-02-11 | 2016-02-24 | 密歇根大学董事会 | 肽组合物和用于治疗患者的方法 |
| EP2780030A4 (en) | 2011-11-17 | 2015-11-18 | Cebix Ab | PEGYLATED C-PEPTIDE |
| RU2522897C1 (ru) * | 2013-04-16 | 2014-07-20 | Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" | Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты) |
| KR101676542B1 (ko) * | 2014-12-30 | 2016-11-16 | 건국대학교 산학협력단 | 프로인슐린의 면역학적 용도 |
| CN104888201B (zh) * | 2015-06-29 | 2018-04-27 | 齐锦生 | 用于防治糖尿病及其慢性并发症的肽类药物 |
| JP7438757B2 (ja) | 2017-02-06 | 2024-02-27 | バイオテンプト・ベー・フェー | 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU166913B (xx) * | 1972-05-15 | 1975-06-28 | ||
| JPS5210872B2 (xx) | 1973-07-14 | 1977-03-26 | ||
| JPS55105653A (en) * | 1978-10-02 | 1980-08-13 | Shionogi & Co Ltd | Tyrosyl c-peptides |
| CA1176158A (en) | 1981-08-27 | 1984-10-16 | Ronald E. Chance | Pharmaceutical formulations comprising human insulin and human c-peptide |
| DE3326473A1 (de) | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
| US4581165A (en) * | 1984-06-14 | 1986-04-08 | Eli Lilly And Company | Anti-diabetic compounds |
| US5104854A (en) | 1989-02-01 | 1992-04-14 | Washington University | Antiviral peptides |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| US5364757A (en) | 1990-05-21 | 1994-11-15 | Administrators Of The Tulane Educational Fund | Methods of supporting a diagnosis of systemic lupus erythematosus |
| IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| JPH05268982A (ja) | 1992-03-27 | 1993-10-19 | Hoechst Japan Ltd | 骨形成作用を有する新規な蛋白質およびその製造法 |
| AU679443B2 (en) | 1992-04-13 | 1997-07-03 | Oklahoma Medical Research Foundation | Methods and reagents for diagnosis of autoantibodies |
| WO1994025071A1 (en) | 1993-05-05 | 1994-11-10 | Keith Rose | Polyoxime compounds and their preparation |
| AT400723B (de) | 1993-08-27 | 1996-03-25 | Biomay Prod & Handel | Rekombinante alternaria alternata allergene |
| AU3094795A (en) | 1994-07-08 | 1996-02-09 | Trustees Of Dartmouth College | Proinsulin peptide compounds for detecting and treating type i diabetes |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB9422175D0 (en) | 1994-11-03 | 1994-12-21 | Univ Dundee | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof |
| GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
| CO4600637A1 (es) | 1996-03-15 | 1998-05-08 | Corixa Corp | Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata |
| US6150500A (en) | 1996-07-12 | 2000-11-21 | Salerno; John C. | Activators of endothelial nitric oxide synthase |
-
1996
- 1996-09-27 SE SE9603533A patent/SE520392C2/sv not_active IP Right Cessation
-
1997
- 1997-09-26 TR TR1999/00694T patent/TR199900694T2/xx unknown
- 1997-09-26 KR KR1019990702585A patent/KR20000048643A/ko not_active Application Discontinuation
- 1997-09-26 ES ES97942119T patent/ES2278394T3/es not_active Expired - Lifetime
- 1997-09-26 DE DE69737065T patent/DE69737065T2/de not_active Expired - Lifetime
- 1997-09-26 WO PCT/GB1997/002627 patent/WO1998013384A1/en active IP Right Grant
- 1997-09-26 IL IL12914397A patent/IL129143A0/xx unknown
- 1997-09-26 BR BR9711573-8A patent/BR9711573A/pt not_active Application Discontinuation
- 1997-09-26 CZ CZ991085A patent/CZ108599A3/cs unknown
- 1997-09-26 AT AT97942119T patent/ATE347562T1/de not_active IP Right Cessation
- 1997-09-26 JP JP10515410A patent/JP2001500893A/ja not_active Ceased
- 1997-09-26 RU RU99108434/14A patent/RU2206336C2/ru not_active IP Right Cessation
- 1997-09-26 NZ NZ335231A patent/NZ335231A/xx unknown
- 1997-09-26 HU HU0000432A patent/HUP0000432A3/hu unknown
- 1997-09-26 EP EP97942119A patent/EP0938503B1/en not_active Expired - Lifetime
- 1997-09-26 DK DK97942119T patent/DK0938503T3/da active
- 1997-09-26 AU AU43915/97A patent/AU741901B2/en not_active Ceased
- 1997-09-26 CA CA002266416A patent/CA2266416C/en not_active Expired - Fee Related
- 1997-09-26 SK SK394-99A patent/SK39499A3/sk unknown
- 1997-09-26 PL PL97332494A patent/PL332494A1/xx unknown
- 1997-09-26 US US09/269,439 patent/US6610649B2/en not_active Expired - Fee Related
-
1999
- 1999-03-23 IS IS5008A patent/IS5008A/is unknown
- 1999-03-26 NO NO991483A patent/NO991483L/no not_active Application Discontinuation
- 1999-04-27 BG BG103362A patent/BG103362A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK39499A3 (en) | 1999-10-08 |
| TR199900694T2 (xx) | 1999-06-21 |
| PL332494A1 (en) | 1999-09-13 |
| CZ108599A3 (cs) | 1999-08-11 |
| IL129143A0 (en) | 2000-02-17 |
| AU741901B2 (en) | 2001-12-13 |
| BR9711573A (pt) | 2000-01-18 |
| US20020107175A1 (en) | 2002-08-08 |
| RU2206336C2 (ru) | 2003-06-20 |
| DK0938503T3 (da) | 2007-04-10 |
| CA2266416A1 (en) | 1998-04-02 |
| ATE347562T1 (de) | 2006-12-15 |
| IS5008A (is) | 1999-03-23 |
| HUP0000432A3 (en) | 2000-10-30 |
| EP0938503A1 (en) | 1999-09-01 |
| KR20000048643A (ko) | 2000-07-25 |
| JP2001500893A (ja) | 2001-01-23 |
| BG103362A (en) | 2000-05-31 |
| NO991483D0 (no) | 1999-03-26 |
| SE9603533D0 (sv) | 1996-09-27 |
| WO1998013384A1 (en) | 1998-04-02 |
| SE520392C2 (sv) | 2003-07-01 |
| AU4391597A (en) | 1998-04-17 |
| DE69737065T2 (de) | 2007-06-28 |
| HUP0000432A2 (hu) | 2000-08-28 |
| US6610649B2 (en) | 2003-08-26 |
| SE9603533L (sv) | 1998-03-28 |
| NZ335231A (en) | 2000-11-24 |
| CA2266416C (en) | 2008-04-29 |
| DE69737065D1 (en) | 2007-01-18 |
| ES2278394T3 (es) | 2007-08-01 |
| EP0938503B1 (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991483L (no) | Insulin C-peptider | |
| Wagstaff et al. | Molecular characterisation of endogenous snake venom metalloproteinase inhibitors | |
| PT93910A (pt) | Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula | |
| BR9710452A (pt) | Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos | |
| GB9519275D0 (en) | Substances and their therapeutic use | |
| BR9910573A (pt) | Compostos antipicornavirais, preparação e uso dos mesmos | |
| NZ332879A (en) | Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes | |
| ATE497390T1 (de) | Neue therapeutische verwendung von smr-1 peptide | |
| GB9422175D0 (en) | Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof | |
| Aquilina et al. | Cysteine is the initial site of modification of α-crystallin by kynurenine | |
| Nousiainen et al. | Characterization of exoskeletal proteins from the American lobster, Homarus americanus | |
| NO974260L (no) | Nye definerte enzymblandinger for oppnåelse av celler og behandling av sår | |
| FI971427A (fi) | Peptidit ja niitä sisältävät farmaseuttiset koostumukset | |
| NO933742L (no) | Humant, benavledet, insulinlignende vekstfaktorbindingsprotein | |
| ATE216707T1 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
| WO1997040073A3 (de) | BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN | |
| BR0308040A (pt) | Composições farmacêuticas e cosméticas compreendendo plgf-1 | |
| AU698242B2 (en) | Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases | |
| Sobolewski et al. | Binding of the basic fibroblast growth factor (bFGF) by soluble components of human umbilical cord. | |
| NO20084140L (no) | DNA-sekvens, RAP-2 bindende protein, isoform, fragment eller analog derav samt anvendelse derav og fremgangsmate for isolering og identifisering av proteiner som kan bli bundet til RAP-2. | |
| DK1340507T3 (da) | Anvendelse af et fibroblastvækstfaktor-bindingsprotein til behandling og diagnosticering af diabetiske sårhelingsforstyrrelser | |
| WO2005005668A3 (en) | Diagnosis and treatment methods related to aging (8a) | |
| WO2002062996A1 (fr) | Nouveau peptide physiologiquement actif et utilisation de ce peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |